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ABSTRACT 
 
Background 
Thrombolysis usage in ischaemic stroke varies across sites. Divergent advice from professional 
guidelines and product labels may contribute.   
 
Methods 
We analysed SITS-International registry patients enrolled January 2010 through June 2016.  We 
grouped sites into organisational tertiles by number of patients arriving ≤2.5h and treated ≤3h, 
percentage arriving ≤2.5h and treated ≤3h, and numbers treated ≤3h.  We assigned scores of 1-3 
(lower/middle/upper) per variable and 2 for on-site thrombectomy.  We classified sites as lower-
efficiency (summed scores 3-5), medium-efficiency (6-8) or higher-efficiency (9-11).   
 
Sites were also grouped by adherence with European product label and ESO guideline: “label 
adherent” (>95% on-label), “guideline adherent” (≥5% off-label, ≥95% on-guideline) or “guideline 
non-adherent” (>5% off-guideline).  We cross-tabulated site-efficiency and adherence.  We 
estimated the potential benefit of universally selecting by ESO guidance, using onset-to-treatment 
time-specific numbers needed to treat for day 90 mRS 0-1. 
 
Results 
56,689 patients at 597 sites were included: 163 sites were higher-efficiency, 204 medium-
efficiency and 230 lower-efficiency. 56 sites were “label adherent”, 204 “guideline adherent” and 
337 “guideline non-adherent”. There were strong associations between site-efficiency and 
adherence (P<0.001).  Almost all “label adherent” sites (55, 98%) were lower-efficiency.  
  
If all patients were treated by ESO guidelines, an additional 17,031 would receive alteplase, 
which translates into 1,922 more patients with favourable 3-month outcomes.  
 
Conclusion 
Adherence with product labels is highest in lower-efficiency sites.  Closer alignment with 
professional guidelines would increase patients treated and favourable outcomes.  Product labels 
should be revised to allow treatment of patients ≤4.5 hours from onset and aged 80 years. 
 
 
 
  
Background 
Thrombolysis with intravenous recombinant tissue plasminogen activator (IV rt-PA) (alteplase; 
Actulyse or Activase) is effective and safe for patients with acute ischaemic stroke, yet only a 
fraction of patients receive treatment1-9.  The product labels for IV rt-PA in Europe (EU) and the 
United States (US) are derived from early randomised controlled trials, which excluded important 
groups10. The EU label restricts treatment to patients under 80 years, whilst the US label 
excludes patients greater than 3 hours from symptom onset.  IV rt-PA is effective and safe within 
4.5 hours of symptom onset11-13 and there is clear treatment benefit in the elderly9,14-18.  
Professional guidance from the European Stroke Organisation (ESO) and American Stroke 
Association (ASA) better reflects the evidence base for alteplase19-21. The ESO recommend 
treatment within 4.5 hours with no age limit, whilst ASA guidance in 2013 excluded patients aged 
>80 years beyond 3 hours, although an update in 2016 acknowledged alteplase is effective within 
4.5 hours in the elderly9,19-21. Thus, patients are often treated off-label22, although this practice is 
not permitted in many countries and the current product labels therefore restrict the number of 
patients that can be treated1,22.   
 
We aimed to assess variation in the use of IV rt-PA within the Safe Implementation of 
Thrombolysis in Stroke International Stroke Thrombolysis Registry (SITS-ISTR), in relation to the 
principal criteria that differ between regional product labels and professional guidelines.  Our 
objective was to assess whether centres’ expertise, measured in terms of efficient patient 
throughput and treatment logistics, is associated with closer adherence to the EU / US drug 
labels and professional guidelines; and to estimate the potential impact on treatment rates and 
clinical outcomes if there were greater alignment of the product labels and professional 
guidelines.  We hypothesised that centres which achieve excellent treatment logistics will adhere 
more closely with professional guidelines rather than strictly observing the product label for IV 
alteplase.   
 
 
Methods 
We conducted a retrospective analysis on individual patient data obtained from the SITS-ISTR 
between January 2010 and June 2016 (Figure 1). SITS-ISTR is a multinational open registry of 
patients with acute ischaemic stroke who received IV rt-PA23. Patients from 597 participating 
centres were included who had complete information on treating hospital and country, age, 
gender, onset-to-treatment time (OTT), total National Institutes of Health Stroke Scale (NIHSS), 
history of diabetes and history of prior stroke. We excluded patients on direct oral anticoagulants 
or with OTT recorded as >6 hours. Baseline characteristics included data on pre-stroke modified 
Rankin Scale (mRS), medical history and medications.  We also gathered data for on-site use of 
thrombectomy. 
 
We grouped sites according to their “selection adherence” of alteplase use: label adherent (>95% 
of patients treated within label), guideline adherent (≥5% of patients treated off-label but ≥95% of 
patients treated within guideline) or guideline non-adherent (>5% of patients treated off-
guideline). We assessed site quality using a tertile based scoring algorithm.  Sites were grouped 
into tertiles according to (i) the volume of patients arriving within 2.5 hours and treated within 3 
hours, (ii) the percentage of patients arriving within 2.5 hours and treated within 3 hours, and (iii) 
the volume of patients treated within 3 hours of stroke onset.  We assigned sites a score for each 
variable: 1 point if the site was within the lower tertile, 2 points for the middle tertile or 3 points for 
the upper tertile. An additional 2 points were allocated for on-site use of thrombectomy.  This 
resulted in a total score between 3 and 11 for each site.  We classified sites with scores of 3 to 5 
as ‘lower efficiency’, 6 to 8 as ‘medium efficiency’ and 9 to 11 as ‘higher efficiency’.  We tested 
associations between site efficiency and selection adherence of alteplase use by cross-tabulation 
and Chi-squared analyses performed in SPSS version 22.0, with a significance level of 5%.  
 
We estimated the potential for clinical benefit if treatment of all patients within our cohort was by 
the professional guideline versus product label for alteplase.  We performed this analysis by 
applying guideline criteria for treatment with IV rtPA to our entire cohort, and compared this to the 
number of patients that would have been treated if the product label criteria were applied.  We 
conducted separate analyses for both European (ESO guideline and EU label) and American 
(AHA guideline and FDA label) criteria applied to the entire dataset.  We calculated the number of 
patients for whom treatment would have been contraindicated by the product label but 
recommended by professional guideline. We stratified such patients according to OTT: within 90 
minutes, 91 to 180 minutes or 181 to 270 minutes.  We used OTT-specific numbers needed to 
treat (NNT) for a day 90 modified Rankin Scale (mRS) of 0-1 to estimate the number of additional 
patients that would achieve a favourable outcome if treatment was universally by professional 
guideline rather than product label (NNT of 4.5 if OTT was 0 to 90 minutes, NNT of 9.0 if OTT 91 
to 180 minutes and NNT of 14.1 if OTT 181 to 270 minutes).  We divided the number of additional 
patients that would be treated within each time window by the corresponding NNT to estimate the 
number of patients that would achieve a favourable outcome.   
 
Results 
We analysed data from 56,689 patients treated at 597 sites during the study period.  Baseline 
characteristics of the patients are shown in table 1.  By our predefined criteria, 163 sites (27%) 
were classified as ‘higher efficiency’, 204 sites (34%) as ‘medium efficiency’ and 230 sites (39%) 
as ‘lower efficiency’.  
 
When analysing selection adherence across all sites by the EU product label and ESO guideline, 
we found that 56 sites (9%) were label adherent, 204 sites (34%) were guideline adherent and 
337 sites (56%) were guideline non-adherent.  Site efficiency was strongly associated with 
selection adherence by European criteria (p<0.001) (Figure 2).  Among the 56 label adherent 
sites, 55 (98%) were lower efficiency and one only (2%) was medium efficiency.  Of the 204 
guideline adherent sites, 92 (45%) were lower efficiency, 75 (37%) were medium efficiency and 
37 (18%) were higher efficiency.  Among the 337 guideline non-adherent sites, 126 (37%) were 
higher efficiency, 128 (38%) were medium efficiency and 83 (25%) were lower efficiency.  When 
we judged use in our mainly European dataset against US product label and ASA guideline 
criteria, a similar pattern emerged except that guideline non-adherence rose (see online 
appendix). 
 
IV rt-PA was administered to 5770 patients (10%) beyond European guideline recommendations.  
This was due to patients treated with a BP greater than guideline recommendations in 4618 
patients (8%), an OTT greater than 4.5 hours in 1047 patients (2%) and a combination of 
elevated BP with an OTT greater than 4.5 hours in 105 patients (0.2%).  Among the 5770 patients 
administered IV rt-PA beyond European guideline recommendations, 3845 (67%) were treated in 
a higher efficiency site, 1644 (28%) in a medium efficiency site and 281 (5%) in a lower efficiency 
site (Figure 3).   
 
Within our cohort, 50,919 patients (90%) would receive thrombolysis if treatment was universally 
delivered by the ESO guideline, compared to 33,888 patients (60%) by the European product 
label.  Thus, an additional 17,031 patients (30%) would receive thrombolysis if treatment was 
universally delivered according to ESO guidance.  This translates into 1,922 patients who would 
achieve a favourable outcome when measured by OTT-specific NNT for a day 90 mRS of 0-1 
(Figure 4).   
 
Discussion 
We have demonstrated that strict adherence with the product label for IV rt-PA is greatest in sites 
that treat lower volumes of patients, have fewer facilities or achieve less impressive in-hospital 
timelines.  Strict adherence with the product label restricts use of IV rt-PA, reducing the number of 
patients that can be treated and, by implication, that may achieve favourable outcomes.  If 
treatment decisions within our cohort were based upon ESO guidelines rather than the European 
drug label, an additional 2620 patients would be treated annually across the 6.5 years studied.  
This translates into an additional 296 patients each year with favourable outcomes. Evidence 
supporting the selection criteria described in the ESO and ASA professional guidelines is robust 
and the conclusions of these organisations agree on all major points19-21.  The drug product labels 
for alteplase require review in both Europe and America, to reflect evidence highlighting the 
efficacy and safety of IV rt-PA in circumstances that were originally considered contraindications 
for thrombolysis1,24,25.  The key issue is that these labels, which simply control marketing activities 
and not prescribing per se, should permit the manufacturers to discuss and educate clinicians on 
the safe treatment of patients within 4.5 hours of symptom onset or aged over 80 years.  Revising 
the European and American product labels to this effect would deliver clinical outcomes 
consistent with those obtained when treating within the current drug labels, with no adverse effect 
on mortality26.  Alignment of educational messages is desirable and should be conveyed amongst 
the medical community9. 
 
Our data demonstrate that less efficient sites have the lowest rates of treatment with alteplase off-
label, which may in part be attributable to less developed regions being unable to treat off-label27.  
This is consistent with findings from a previous study using SITS-ISTR data, which demonstrated 
that higher volume centres have the greatest rates of treatment with alteplase off-label28.  
Improving the quality of treatment for every patient with acute stroke is a priority of the ESO and 
World Stroke Organisation (WSO), with the Angels Initiative recently introduced to help achieve 
this goal.  Education of clinicians and revision of the product labels for alteplase will help our 
effort to deliver excellent care for patients with acute ischaemic stroke worldwide.    
 
It is concerning that we observed high rates of treatment with alteplase beyond professional 
guidelines.  Off-guideline treatment was administered to 10% of patients by European criteria, 
which was driven by treatment above BP recommendations and beyond 4.5 hours.  Treatment 
with alteplase off-guideline exposes patients to an increased risk of mortality that is not offset by 
potential for clinic benefit26 and clinicians should avoid this practice.  Violations of pre-treatment 
BP parameters are associated with an increased risk of bleeding and BP should be controlled 
before treatment with IV rt-PA to reduce the risk of symptomatic intracerebral haemorrhage24,25.  
Most off-guideline treatment was in higher efficiency sites and programmes discouraging this 
approach should include all the stroke community. 
 We designed a measure of site efficiency that acts as a marker of site quality.  We allocated 
points for efficient treatment logistics, the volume and proportion of patients treated promptly and 
on-site use of thrombectomy.  Our aim was to stratify sites according to treatment logistics, 
patient volume and delivery of comprehensive acute stroke care.  Various indicators can be used 
to assess quality of acute stroke unit care29, although not all of these data are available within 
SITS-ISTR.  Our measure of site quality is arbitrary and uses objective information available 
within SITS-ISTR defined before we accessed the data, which is thus a weakness of our study.  
The criterion for site quality includes measures derived mainly from OTT and volume of patients, 
which may disadvantage centres with longer out-of-hospital transportation logistics and smaller 
sites.   We defined BP based upon that recorded at baseline within the SITS registry and cannot 
be certain that BP was not lowered prior to thrombolysis, which is a limitation. 
 
A further limitation is the retrospective and observational design, although the large volume and 
accuracy of data collected within SITS-ISTR allows for robust statistical analyses23.  SITS-ISTR is 
a predominantly European cohort which is important when considering the generalisability of our 
findings.  Patients managed outside Europe are often in countries with less experienced centres 
and our results are relevant to these regions.  Finally, SITS-ISTR includes patients voluntarily 
registered by participating centres which could contribute to selection bias, although data from 
SITS are robust and have been used in similar studies14,23,28. 
 
Conclusion 
We confirmed that strict adherence with the more restrictive product label for alteplase was 
concentrated among the least active or efficient hospitals, whereas more experienced sites offer 
treatment based on according professional guideline criteria. However, we found that the busiest 
and most efficient sites are treating beyond even the professional guidelines, potentially exposing 
these patients to a risk of increased mortality that is not offset by potential for clinical benefit. We 
conclude that review and alignment of the marketing approvals for alteplase in acute ischaemic 
stroke with the current recommendations of the professional guidelines, to allow treatment of 
patients ≤4.5 hours from onset and aged ≥80 years, should be coupled with enhanced education 
to operate within those guidelines to maximise the population safety and effectiveness of 
thrombolysis for stroke. 
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Figure 1 
 
Selection process of the study population. 
 
 
 
SITS-ISTR Safe Implementation of Thrombolysis in Stroke  
International Stroke Thrombolysis Registry 
DOAC Direct Oral Anti-Coagulant 
NIHSS National Institutes of Health Stroke Scale 
OTT Onset-to-Treatment Time 
 
 
Figure 2 
 
Site efficiency and selection adherence with EU Product Label and ESO Guideline. 
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Figure 3 
 
The percentages of patients treated off-guideline grouped by site efficiency, according to ESO 
guideline criteria (n=5,770). 
 
 
 
Figure 4 
 
The percentage of patients that would be treated if the decision was based on ESO guidance 
versus EU product label: an additional 17,031 patients (30%) would be treated if the decision 
was based upon ESO guidance, which translates into 1,922 patients achieving favourable 
outcomes when estimated using OTT-specific NNT for a day 90 mRS of 0-1.  
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Table 1 
Baseline characteristics of the cohort 
 
Characteristic Measure 
Entire Cohort 
N=56689 
Age (years) 
 
Mean 
(SD) 
69.8 
(13.1) 
Sex (male)  
 
n 
(%) 
30969 
(55%) 
Baseline NIHSS 
 
Median 
(IQR) 
10 
(6-16) 
Onset to treatment time (minutes) 
 
Median 
(IQR) 
151 
(118-195) 
Atrial fibrillation 
 
n 
(%) 
11947 
(21%) 
Hypertension 
n 
(%) 
37641 
(66%) 
Diabetes mellitus 
n 
(%) 
10604 
(19%) 
Hypercholesterolaemia 
n 
(%) 
16455 
(29%) 
Heart failure 
n 
(%) 
4702 
(8%) 
Smoker 
n 
(%) 
9347 
(17%) 
Previous stroke or TIA 
n 
(%) 
9067 
(16%) 
IQR indicates interquartile range; NIHSS, National Institutes of Health Stroke Scale 
 
 
Appendix Figure 1 
 
Site efficiency and selection adherence with American Product Label and ASA guideline. 
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Appendix Figure 2 
 
The percentage of patients treated off-guideline grouped by site efficiency, according to ASA 
guideline criteria (n=10,690). 
 
 
 
Appendix Figure 3 
 
The percentage of patients that would be treated if the decision was based on ASA guidance 
versus the American product label: there were 13,070 patients (23%) for whom treatment would 
have been recommended by ASA guidance but not the American product label.  Amongst these 
13,070 patients, 1,114 would achieve a favourable outcome when estimated by OTT-specific NNT 
for a day 90 mRS of 0-1.  
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